Effect of Flavonoid-rich Extract of Tamarix Articulata Vahl. on Glucose and Lipid Metabolism in Normal and Diabetic Rats.

Q2 Medicine

Cardiovascular and Hematological Agents in Medicinal Chemistry Pub Date : 2018-01-01 DOI:10.2174/1871525717666181211143858

Morad Hebi, Lhoussaine Hajji, Mohamed Eddouks

{"title":"Effect of Flavonoid-rich Extract of Tamarix Articulata Vahl. on Glucose and Lipid Metabolism in Normal and Diabetic Rats.","authors":"Morad Hebi, Lhoussaine Hajji, Mohamed Eddouks","doi":"10.2174/1871525717666181211143858","DOIUrl":null,"url":null,"abstract":"Objective: The present study was carried out in order to evaluate the antidiabetic and antihyperlipidemic potential of Flavonoid-Rich Extract of Tamarix articulata (FRETA) in both normal and Streptozotocin (STZ)-induced diabetic rats.Material and methods: Normal and diabetic rats were treated with the FRETA for 7 days. At the end of treatment, a range of parameters was tested including blood lipid profile, histopathological changes in both liver and pancreas and Oral Glucose Tolerance Test (OGTT).Results: The blood glucose levels were lowered in both normal and diabetic rats treated with FRETA. Single oral administration of FRETA reduced blood glucose levels significantly in both normal and diabetic rats six hours after administration (P < 0.001; P < 0.0001 respectively). Furthermore, blood glucose levels were decreased significantly (P < 0.0001) in diabetic rats after 7 days of treatment. According to the oral glucose tolerance test, FRETA (5 mg/kg) was shown to prevent significantly the increase in blood glucose levels in diabetic treated rats. In addition, FRETA (5 mg/kg) showed a strong hypolipidemic effect both in normal and STZ rats after 7 days of once daily oral treatment. FRETA induced a significant decrease of plasma triglyceride and total cholesterol concentrations both in normal and diabetic rats. In contrast, plasma HDL-c levels were increased significantly (P < 0.0001) both in normal and diabetic rats. In addition, FRETA showed a remarkable in vitro antioxidant activity and revealed the inhibitory concentration of 50% of free radicals (IC50) of 31.92 µg/ml.Conclusion: In diabetic rats, flavonoids from Tamarix articulata showed antidiabetic and hypolipidemic activities.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"16 2","pages":"94-105"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871525717666181211143858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 9

Abstract

Objective: The present study was carried out in order to evaluate the antidiabetic and antihyperlipidemic potential of Flavonoid-Rich Extract of Tamarix articulata (FRETA) in both normal and Streptozotocin (STZ)-induced diabetic rats.

Material and methods: Normal and diabetic rats were treated with the FRETA for 7 days. At the end of treatment, a range of parameters was tested including blood lipid profile, histopathological changes in both liver and pancreas and Oral Glucose Tolerance Test (OGTT).

Results: The blood glucose levels were lowered in both normal and diabetic rats treated with FRETA. Single oral administration of FRETA reduced blood glucose levels significantly in both normal and diabetic rats six hours after administration (P < 0.001; P < 0.0001 respectively). Furthermore, blood glucose levels were decreased significantly (P < 0.0001) in diabetic rats after 7 days of treatment. According to the oral glucose tolerance test, FRETA (5 mg/kg) was shown to prevent significantly the increase in blood glucose levels in diabetic treated rats. In addition, FRETA (5 mg/kg) showed a strong hypolipidemic effect both in normal and STZ rats after 7 days of once daily oral treatment. FRETA induced a significant decrease of plasma triglyceride and total cholesterol concentrations both in normal and diabetic rats. In contrast, plasma HDL-c levels were increased significantly (P < 0.0001) both in normal and diabetic rats. In addition, FRETA showed a remarkable in vitro antioxidant activity and revealed the inhibitory concentration of 50% of free radicals (IC50) of 31.92 µg/ml.

Conclusion: In diabetic rats, flavonoids from Tamarix articulata showed antidiabetic and hypolipidemic activities.

查看原文本刊更多论文

黄酮类化合物对柽柳提取物的影响。对正常和糖尿病大鼠糖脂代谢的影响。

目的:探讨富黄酮柽柳提取物(FRETA)对正常及链脲佐菌素(STZ)诱导的糖尿病大鼠的降糖和降血脂作用。材料与方法:正常大鼠和糖尿病大鼠分别给予FRETA治疗7 d。在治疗结束时，检测一系列参数，包括血脂，肝脏和胰腺的组织病理学变化以及口服葡萄糖耐量试验(OGTT)。结果:FRETA对正常大鼠和糖尿病大鼠的血糖均有降低作用。单次口服FRETA可显著降低正常和糖尿病大鼠给药后6小时的血糖水平(P < 0.001;P < 0.0001)。治疗7 d后，糖尿病大鼠血糖水平明显降低(P < 0.0001)。根据口服葡萄糖耐量试验，FRETA (5 mg/kg)可显著预防糖尿病大鼠血糖水平升高。此外，FRETA (5 mg/kg)在正常大鼠和STZ大鼠每日口服1次7天后均显示出较强的降血脂作用。FRETA诱导正常和糖尿病大鼠血浆甘油三酯和总胆固醇浓度显著降低。相比之下，正常和糖尿病大鼠血浆HDL-c水平均显著升高(P < 0.0001)。此外，FRETA还具有显著的体外抗氧化活性，对50%自由基的抑制浓度(IC50)为31.92µg/ml。结论:柽柳黄酮对糖尿病大鼠具有抗糖尿病和降血脂作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Agents in Medicinal Chemistry Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry. Cardiovascular & Hematological Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.